用户名： 密   码：
注册 | 忘记密码？
药品详细

Ximelagatran(希美加群)

化学结构式图
中文名
希美加群
英文名
Ximelagatran
分子式
C24H35N5O5
化学名
ethyl 2-{[(1R)-1-cyclohexyl-2-[(2S)-2-[({4-[(Z)-N'-hydroxycarbamimidoyl]phenyl}methyl)carbamoyl]azetidin-1-yl]-2-oxoethyl]amino}acetate
分子量
Average: 473.5652
Monoisotopic: 473.263819255
CAS号
192939-46-1
ATC分类
B01A 抗血栓药
药物类型
small molecule
阶段
approved, withdrawn
商品名
同义名
基本介绍

Ximelagatran (Exanta® or Exarta®, H 376/95) is an anticoagulant that has been investigated extensively as a replacement for warfarin that would overcome the problematic dietary, drug interaction, and monitoring issues associated with warfarin therapy. In 2006, its manufacturer AstraZeneca announced that it would not attempt to market ximelagatran after reports of hepatotoxicity (liver damage) during trials, and to discontinue its distribution in countries where the drug had been approved.

生产厂家
    封装厂家
    参考
    Synthesis Reference Not Available
    General Reference
    1. Eriksson H, Wahlander K, Gustafsson D, Welin LT, Frison L, Schulman S: A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost. 2003 Jan;1(1):41-7. Pubmed
    2. Weitz JI: New anticoagulants for treatment of venous thromboembolism. Circulation. 2004 Aug 31;110(9 Suppl 1):I19-26. Pubmed
    3. Francis CW, Berkowitz SD, Comp PC, Lieberman JR, Ginsberg JS, Paiement G, Peters GR, Roth AW, McElhattan J, Colwell CW Jr: Comparison of ximelagatran with warfarin for the prevention of venous thromboembolism after total knee replacement. N Engl J Med. 2003 Oct 30;349(18):1703-12. Pubmed
    4. Bergqvist D, Solhaug JH, Holmdahl L, Eriksson UG, Andersson M, Boberg B, Ogren M: Pharmacokinetics, preliminary efficacy and safety of subcutaneous melagatran and oral ximelagatran : a multicentre study of thromboprophylaxis in elective abdominal surgery. Clin Drug Investig. 2004;24(3):127-36. Pubmed
    5. Koscielny J, Kiesewetter H, Jorg I, Harenberg J: Ximelagatran for treatment and prophylaxis of recurrent events in deep vein thrombosis. Clin Appl Thromb Hemost. 2007 Jul;13(3):299-307. Pubmed
    剂型
    规格
    化合物类型
    Type small molecule
    Classes
    • Benzene and Derivatives
    • Polypeptides
    Substructures
    • Carboxylic Acids and Derivatives
    • Hydroxy Compounds
    • Acetates
    • Aliphatic and Aryl Amines
    • Amino Ketones
    • Ethers
    • Benzene and Derivatives
    • Polypeptides
    • Heterocyclic compounds
    • Aromatic compounds
    • Carboxamidines
    • Carboxamides and Derivatives
    • Amino Acids
    • Imines
    • Azetidines
    适应症
    药理
    Indication For the treatment of acute deep vein thrombosis.
    Pharmacodynamics Not Available
    Mechanism of action Ximelagatran was the first member of the drug class of direct thrombin inhibitors that can be taken orally. It acts solely by inhibiting the actions of thrombin. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran.
    Absorption Rapidly absorbed by the small intestine with an oral bioavailability of 20%.
    Volume of distribution Not Available
    Protein binding Not Available
    Metabolism
    Hepatic. Ximelagatran is a prodrug, being converted in vivo to the active agent melagatran. This conversion takes place in the liver and many other tissues through dealkylation and dehydroxylation (replacing the ethyl and hydroxyl groups with hydrogen).
    Route of elimination Not Available
    Half life 3-5 hours
    Clearance Not Available
    Toxicity Hepatotoxicity (liver damage) was reported during trials.
    Affected organisms
    • Humans and other mammals
    Pathways
    Pathway Name SMPDB ID
    Smp00279 Ximelagatran Pathway SMP00279
    理化性质
    Properties
    State solid
    Experimental Properties Not Available
    Predicted Properties
    Property Value Source
    water solubility 8.45e-02 g/l ALOGPS
    logP 1.35 ALOGPS
    logP 0.87 ChemAxon
    logS -3.8 ALOGPS
    pKa (strongest acidic) 9.64 ChemAxon
    pKa (strongest basic) 5.48 ChemAxon
    physiological charge 0 ChemAxon
    hydrogen acceptor count 7 ChemAxon
    hydrogen donor count 4 ChemAxon
    polar surface area 146.35 ChemAxon
    rotatable bond count 11 ChemAxon
    refractivity 126.57 ChemAxon
    polarizability 52.15 ChemAxon
    药物相互作用
    食物相互作用
    Not Available

    返回 | 收藏